Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients with CLL

被引：14
|
作者：
Wierda, W [1 ]
Faderl, S [1 ]
O'Brien, S [1 ]
Cortes, J [1 ]
Ferrajoli, A [1 ]
Giles, F [1 ]
Andreff, M [1 ]
Koller, C [1 ]
Kantarjian, H [1 ]
Keating, M [1 ]
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.340.340
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
340
引用
收藏
页码：101A / 101A
页数：1
相关论文
共 50 条
  • [31] NAVITOCLAX (ABT-263) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE/RITUXIMAB (FCR) OR BENDAMUSTINE/RITUXIMAB (BR): A PHASE 1 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Kipps, T.
    Swinnen, L.
    Wierda, W.
    Jones, J.
    Coutre, S.
    Smith, M.
    Yang, J.
    Cui, Y.
    Chyla, B.
    Busman, T.
    Enschede, S.
    Humerickhouse, R.
    HAEMATOLOGICA, 2012, 97 : 219 - 219
  • [32] Concurrent Use of Aspirin with the Fludarabine, Cyclophophamide, Rituximab (FCR) Regimen Improves Outcome in Patients with Relapsed/Refractory CLL
    Chae, Young Kwang
    Trinh, Long Xuan
    Keating, Michael J.
    Estrov, Zeev
    BLOOD, 2012, 120 (21)
  • [33] Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients
    Kutsch, Nadine
    Holmes, Emily Eva
    Robrecht, Sandra
    Schueler, Gudrun
    Vehling-Kaiser, Ursula
    Decker, Thomas
    Mueller-Hagen, Sigrun
    Heinisch, Karin
    Boettcher, Sebastian
    Ritgen, Matthias
    Kreuzer, Karl-Anton
    Stilgenbauer, Stephan
    Fink, Anna Maria
    Fischer, Kirsten
    Eichhorst, Barbara
    Hallek, Michael
    Wendtner, Clemens-Martin
    LEUKEMIA & LYMPHOMA, 2023, 64 (02) : 478 - 482
  • [34] Continuous infusion/subcutaneous alemtuzumab (Campath-1H) plus rituximab is active for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)
    Faderl, S
    Ferrajoli, A
    Wierda, W
    Ravandi, F
    O'Brien, S
    Manero, GG
    Thomas, DA
    Browning, ML
    Keating, MJ
    BLOOD, 2005, 106 (11) : 831A - 831A
  • [35] Long-Term Results of Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
    Badoux, Xavier
    Keating, Michael J.
    Ferrajoli, Alessandra
    Lerner, Susan
    Wang, Xuemei
    O'Brien, Susan
    Wierda, William G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (03): : E35 - E35
  • [36] Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy Is a Safe and Active Regimen for Relapsed/Refractory CLL with in Vivo Mechanism of Action for Combination Chemotherapy
    Wierda, William G.
    Balakrishnan, Kumudha
    Ferrajoli, Alessandra
    O'Brien, Susan
    Burger, Jan A.
    Kadia, Tapan M.
    Cortes, Jorge E.
    Tambaro, Francesco Paolo
    Jalayer, Annette
    Lerner, Susan
    Keating, Michael J.
    Gandhi, Varsha V.
    BLOOD, 2012, 120 (21)
  • [37] Alemtuzumab (Campath) in relapsed or refractory CLL or PLL.
    McCune, SL
    Gockerman, JP
    Moore, JO
    deCastro, CM
    Bass, AJ
    Chao, NJ
    Long, GD
    Vredenburgh, JJ
    Gasparetto, C
    Adams, DB
    Payne, NP
    Rizzieri, DA
    BLOOD, 2001, 98 (11) : 290B - 291B
  • [38] Combined chemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) for relapsed or untreated progressive chronic lymphocytic leukemia (CLL). A single center experience.
    Pavlovsky, S
    Pavlovsky, C
    Pardo, L
    Sapia, S
    Fernandez, II
    Juni, M
    BLOOD, 2005, 106 (11) : 340B - 340B
  • [39] Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
    Faderl, S
    Thomas, DA
    O'Brien, S
    Garcia-Manero, G
    Kantarjian, HM
    Giles, FJ
    Koller, C
    Ferrajoli, A
    Verstovsek, S
    Pro, B
    Andreeff, M
    Beran, M
    Cortes, J
    Wierda, W
    Tran, N
    Keating, MJ
    BLOOD, 2003, 101 (09) : 3413 - 3415
  • [40] EFFICACY OF COMBINATION FLUDARABINE AND ALEMTUZUMAB IN PATIENTS WITH RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
    Zagoskina, T.
    Zotina, E.
    Malykh, O.
    HAEMATOLOGICA, 2012, 97 : 305 - 305
12345